Donafenib Combined With Anti-PD-1 Antibody for Neoadjuvant Therapy in Locally Advanced Thyroid Cancer
Clinical trial NCT06787911 · RECRUITING
Trial details
- NCT number
- NCT06787911
- Sponsor
- Yu Wang
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-07-24
- Primary completion
- 2025-05-31
- Enrollment
- 14
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.